Mandate

Vinge has advised CAREL Industries S.p.A in connection with acquisition

CAREL Industries S.p.A has entered into a binding agreement to acquire 82.4% stake in Kiona Holding AS, a leading Norwegian Software as a Service (“SaaS”) provider of prop-tech solutions for energy consumption optimization and building digitalization in retail & industrial refrigeration, public, commercial and multi-residential facilities. The acquisition consideration implies a 100% enterprise value of NOK 2,350,000,000 (c. SEK 2,428,255,000).

Vinge acted as counsel to CAREL with respect to Swedish matters in the transaction. Vinge advised CAREL alongside Thommessen.

CAREL, based in Italy and listed on the Milan stock exchange, is a global leader in the design, production and marketing of technologically advanced components and solutions for excellent energy efficiency in the control of heating, ventilation, and air conditioning (HVAC) and refrigeration equipment and systems.

Vinge’s team consisted mainly of Henrik Borna (M&A / IT), Niklas Törnell (M&A), Jonatan Karlsson (M&A) and Sophia Reutercrona (Employment).

 

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026